ACI
MGNX icon

AMP Capital Investors’s MacroGenics MGNX Stock Holding History

AMP Capital Investors’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-7,145
Closed -$210K – 1264
2016
Q3 		$210K Buy
+7,145
New +$213K ﹤0.01% 1165

Other funds holding MGNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AMP Capital Investors's MGNX Position: Q4 2016 in Review

AMP Capital Investors sold out of MacroGenics (MGNX) in Q4 2016, closing a stake of 7,145 shares — an estimated $210K sold.

AMP Capital Investors first reported a position in MGNX in Q3 2016 and held it in 1 quarter. The position peaked at $210K in Q3 2016. 131 funds tracked by Wall St. Rank hold MGNX as of Q4 2016.

  • AMP Capital Investors reported no remaining MacroGenics position as of Q4 2016 after selling out during the quarter.
  • AMP Capital Investors sold 7,145 MacroGenics shares in Q4 2016, an estimated $210K.
  • AMP Capital Investors first reported a position in MacroGenics in Q3 2016 and held it in 1 quarter.
  • AMP Capital Investors's MacroGenics position peaked at $210K in Q3 2016.
  • 131 funds tracked by Wall St. Rank held MacroGenics as of Q4 2016.

Based on AMP Capital Investors's 13F filing for Q4 2016, filed 13 Feb 2017.